Lurtotecan Completed Phase 2 Trials for Small Cell Carcinoma / Small Cell Lung Cancer (SCLC) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00046787Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer